# DESCRIPTION

- introduce invention for diagnosing and/or prognosing Parkinson's disease dementia (PDD)

## BACKGROUND OF THE INVENTION

- define Parkinson's disease (PD)
- describe symptoms of PD
- discuss prevalence of PD
- explain cognitive disorders in PD
- describe dementia in PD
- discuss impact of dementia on patients and caregivers
- highlight need for early diagnosis and treatment
- describe neuropathology of PD dementia (PDD)
- discuss Lewy bodies and alpha-synuclein
- explain formation of alpha-synuclein containing inclusion bodies
- describe topographical extent of lesions
- discuss possible link between neurotoxicity, aggregation, and propagation
- summarize attempts to improve early diagnosis of PDD
- discuss limitations of current neurochemical profile
- highlight need for laboratory-based tests for diagnosis and prognosis of PDD
- introduce optimized protocol for proteomic analysis of cerebrospinal fluid sample

## SUMMARY OF THE INVENTION

- introduce method for diagnosing and/or prognosing PDD
- describe molecule for detecting O-linked glycomoieties
- introduce means for diagnosis and/or prognosis of PDD
- describe kit for diagnosis and/or prognosis of PDD

## DETAILED DESCRIPTION OF THE INVENTION

- disclaim limitations of invention
- define terminology
- incorporate references by reference
- describe elements of invention
- explain permutations of elements
- define "comprise" and variations
- define singular and plural forms
- describe inventors' surprising finding
- introduce method for diagnosing PDD
- describe step of detecting O-glycosylation
- describe step of detecting sialic acid level
- define "diagnosing PDD"
- define "prognosing PDD"
- define "differential diagnosing"
- define "Parkinson's disease"
- define "Parkinson's disease dementia"
- define "protein comprising a Ser/Thr motive"
- describe O-linked glycosylation
- describe protein isoforms
- describe posttranslational modifications
- define "glycosylated isoform"
- describe Serpin family members
- describe Serpin A1
- describe Serpin A1 isoforms
- describe Serpin A1 variants
- describe sequence identity of variants
- describe posttranslational modifications of proteins
- define sialic acid
- describe sialic acid structure
- introduce nomenclature system
- explain abbreviations
- describe terminal sialic acid
- describe oligosialic acid
- describe polysialic acid
- explain linkages between Sia units
- describe sialidase
- introduce Serpin A1
- describe posttranslational modifications
- list isoforms of Serpin A1
- describe mature form of Serpin A1
- describe proteolytic processing
- describe structure of antennas
- describe detection of isoforms
- introduce Serpin A1 specific antibody
- describe binding region of antibody
- define corresponding residues
- explain alignment tools
- describe best sequence alignment
- introduce O-glycosylated protein
- describe detection of O-glycosylation
- describe analysis of glycomoieties
- describe mass spectroscopy
- describe determination of glycosylated isoforms
- describe hypersialylated O-linked glycomoieties
- describe increased number of glycosylated isoforms
- describe molecule weight of glycosylated Serpin A1
- describe level of sialic acid
- describe biological sample
- describe body fluid sample
- describe tissue sample
- describe cell sample
- describe weight of tissue sample
- describe number of cells in cell sample
- define subject
- specify subject types
- define control value
- specify control value types
- describe 2D gel electrophoreses
- determine Serpin A1 isoforms
- specify preferred control values
- describe method for diagnosing PDD
- specify preferred control values for PDD
- describe method for differential diagnosing
- specify preferred control values for differential diagnosing
- describe O-linked glycomoieties
- specify preferred O-linked glycomoieties
- describe biological sample types
- specify preferred control subjects
- describe identification of PDD
- specify preferred increase in glycosylated isoforms
- specify preferred increase in sialic acid level
- describe particularly preferred embodiment
- define term "increased compared to a control"
- explain detection of glycosylation and/or structure
- diagnose and/or prognose PDD
- introduce immunoassay
- introduce gel electrophoresis
- introduce spectrometry
- introduce chromatography
- describe liquid chromatography-mass spectrometry
- describe 2D immunoblot
- explain purification with affinity chromatography
- define 1D gel electrophoresis
- describe SDS-PAGE
- describe native gel electrophoresis
- describe isoelectric focusing
- describe 2D gel electrophoresis
- explain detection of proteins
- describe silver staining
- describe Coomassie Blue staining
- introduce Western blotting
- describe detection methods
- introduce enzyme-linked immunosorbent assay
- describe mass spectrometry
- describe laser desorption mass spectrometry
- describe matrix-assisted laser desorption/ionization mass spectrometry
- describe surface-enhanced laser desorption/ionization mass spectrometry
- describe tandem mass spectrometry
- define signal
- describe mass spectrometry embodiments
- describe tandem mass tags embodiments
- determine glycosylated isoforms using 2D gel electrophoresis
- detect separated proteins using silver or Coomassie Blue staining
- compare glycosylated isoforms to control
- determine glycosylated isoforms using Western Blot
- detect label/tag using chemiluminescent or colorimetric reactions
- compare glycosylated isoforms to control
- determine sialic acid level using 1D gel electrophoresis
- detect sialic acid using Western Blot
- evaluate sialic acid level using densitometry or spectrophotometry
- compare sialic acid level to control
- determine sialic acid level using 2D gel electrophoresis
- detect sialic acid using Western Blot
- evaluate sialic acid level using densitometry or spectrophotometry
- compare sialic acid level to control
- describe antibodies according to the second aspect
- describe 1D or 2D gel electrophoresis with sialidase enzyme treatment
- define sialidase enzyme
- describe sialidase enzyme treatment
- describe detection of shift in sialylated Ser/Thr motive proteins
- describe preferred proteins comprising Ser/Thr motive
- describe amino acid sequences of preferred proteins
- define Serpin A8 and Fetuin A variants
- define Ceruloplasmin variants
- define Serpin F1 variants
- define Haptoglobin variants
- define Zinc-alpha-2 glycoprotein variants
- describe alignment tools
- specify method sensitivity
- define sensitivity
- describe diagnosis and prognosis
- specify preferred embodiment of method
- introduce second aspect of invention
- define molecule for detecting O-linked glycomoieties
- describe detected glycan structures
- specify preferred molecule properties
- describe molecule detection capabilities
- define biological sample
- define protein comprising a Ser/Thr motive
- define subject
- describe molecule types
- define peptide
- define polypeptide
- define protein
- define small molecule
- describe molecule detection capabilities
- conclude molecule description
- define molecule binding to Ser/Thr motive protein
- describe binding to epitope and/or glycan structure
- specify binding to sialic acid on protein
- describe detection of O-glycosylation and diagnosis of PDD
- specify binding to all glycosylated isoforms and sialic acid structures
- describe molecule binding to sialic acid and glycan structures
- specify molecule binding to amino acid sequence and sialic acid
- describe molecule as protein, polypeptide, peptide, or small molecule
- specify sialic acid binding molecule as antibody or fragment
- describe amino acid sequence binding molecule as antibody or fragment
- define synthetic peptide or polypeptide
- define recombinant peptide or polypeptide
- define darpin
- define anticalin
- define lectin
- describe selection of molecules by screening
- describe testing of molecule binding by FRET, co-immunoprecipitation, or ELISA
- describe ELISA-based experiment for binding analysis
- describe verification of binding by antibodies or labels
- define antibody or fragment thereof
- describe types of antibodies and fragments
- describe production of antibodies
- describe primary and secondary antibodies
- specify binding of Serpin A1 specific molecule to N-terminal region
- specify binding of molecule to specific amino acid positions
- specify binding of molecule to Neu5Ac(alpha1-6)Gal(beta1-4)GlcNAc structure
- specify binding of molecule to core structure of Serpin A1
- conclude description of molecule binding to Serpin A1 isoforms
- define Serpin A1 specific molecule
- describe labeling of molecule
- introduce mass spectrometry probe
- explain mass spectrometry procedure
- describe selection of synthetic peptide
- introduce third aspect of invention
- describe means for diagnosis and prognosis
- define biological sample and subject
- describe solid support
- introduce immobilization of molecule
- describe biochip/microarray and beads
- specify diameter of beads
- define attached and immobilized
- describe covalent and non-covalent binding
- introduce multiple molecules
- describe attachment to biochip or beads
- specify binding to specific protein region
- introduce antibody
- describe use in method for detecting O-glycosylation
- specify binding to glycosylated isoforms
- describe 1D and 2D gel electrophoresis
- introduce mass spectrometry probe for specific isoform
- describe detection of sialic acid level
- introduce labeled antibody
- describe evaluation of sialic acid level
- compare to control level
- introduce specific sialic acid structure
- describe isolation of glycosylated isoforms
- describe binding verification
- describe detection of glycosylated isoforms
- compare to control number
- diagnose PDD
- describe advantages of invention
- conclude invention
- define protein comprising Ser/Thr motive
- specify preferred proteins
- introduce kit for diagnosis and/or prognosis of PDD
- define kit of parts
- describe detection of O-glycosylation and sialic acid level
- specify means for detection
- describe 1D gel electrophoresis
- describe 2D gel electrophoresis
- explain isoelectric focusing
- describe use of sialidase enzyme
- specify reporter-means
- describe data carrier
- specify control value
- describe instructions for method
- describe quality information material
- describe warnings
- specify amino acid sequences
- introduce use of molecule, means, or kit
- describe molecule composition or set
- introduce molecule for detecting O-glycosylation
- describe modifications and variations
- specify scope of invention
- describe embodiments
- describe obvious modifications
- describe intention to cover modifications
- conclude invention description

## EXAMPLES

- introduce examples for illustrative purposes

### Example 1

- describe subjects and CSF samples
- outline ethics committee approvals
- detail patient examinations and neuropsychological tests
- summarize patient groups and characteristics
- describe neuropathology samples
- outline CyDye labeling and 2D-DIGE methodology
- describe 2D gel electrophoresis and imaging
- outline in-gel digestion and mass spectrometry
- detail database search and protein identification
- describe Western blot methodology
- outline calculations and statistics
- describe results of 2D-DIGE experiments
- identify regulated proteins
- describe Western blot validation
- outline 2D Western blot methodology
- identify Serpin A1 as a regulated protein
- describe isoform pattern of Serpin A1
- outline reproducibility of results
- describe sensitivity and specificity of Serpin A1
- outline diagnostic potential of Serpin A1
- describe additional spots in PDD patients
- outline ROC analysis
- describe diagnostic sensitivity and specificity
- outline predictive value of Serpin A1 isoform pattern
- discuss Parkinson's dementia diagnosis
- outline limitations of current diagnostic methods
- describe need for laboratory markers
- outline potential of CSF analysis
- describe Serpin A1 in Alzheimer's disease and dementia with Lewy bodies
- outline biochemical verification of Serpin A1 regulation
- describe isoform distribution of Serpin A1
- outline predictive value of Serpin A1 isoform pattern
- describe verification of results in larger cohort
- outline potential of Serpin A1 as a diagnostic marker
- discuss implications of results
- conclude on the diagnostic potential of Serpin A1

### Example 2

- characterize Serpin A1 isoforms LC-MS/MS
- describe sample preparation for LC-MS/MS
- outline LC-MS/MS analysis parameters
- describe PNGase F and neuraminidase digests
- outline neuraminidase assay
- summarize results of LC-MS/MS analysis
- identify posttranslational modifications
- perform PNGase F digest
- perform neuraminidase digest
- discuss results of digests
- conclude hypersialylation of Serpin A1 isoforms

### Example 3

- analyze Serpin A1 expression in human cortex tissues
- correlate Serpin A1 spots with tau-values

